Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01844856 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections
A Phase 3 study of Complicated Intra-abdominal Infections, sponsored by Tetraphase Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 541
- Enrollment target
- 20
- Study locations
NCT01844856 is a Phase 3 study of Complicated Intra-abdominal Infections that has completed, run by Tetraphase Pharmaceuticals. The registered enrollment target is 541 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT01844856, a Phase 3 study of Complicated Intra-abdominal Infections, has completed, sponsored by Tetraphase Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 541 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy, safety, and pharmacokinetics of eravacycline compared with ertapenem in the treatment of adult complicated intra-abdominal infections (cIAI).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Eravacycline
- DRUG Ertapenem
Study Locations (20)
California
- - Glendale
- - La Mesa
- - Los Angeles
- - Torrance
Ohio
- - Cleveland
- - Columbus
- - Weston
Alabama
- - Florence
- - Mobile
Massachusetts
- - Boston
- - Springfield
New Jersey
- - Camden
- - Teaneck
Illinois
- - Aurora
Indiana
- - Carmel
Minnesota
- - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 541 participants |
| Start Date | 2013-08 |
| Est. Completion | 2014-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01844856
The ClinicalTrials.gov registry entry for NCT01844856 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 541 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tetraphase Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Complicated Intra-abdominal Infections appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01844856 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Ohio, Alabama.
Frequently Asked Questions
What is clinical trial NCT01844856 about?
NCT01844856 is a clinical study titled "Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections". This is a Phase 3, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy, safety, and pharmacokinetics of eravacycline compared with ertapenem in the treatment of adult complicated intra-abdominal infections (cIAI).
What is the current status of trial NCT01844856?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 541 participants. The study started on 2013-08. Estimated completion is 2014-08.
What conditions does trial NCT01844856 study?
This clinical trial studies the following conditions: Complicated Intra-abdominal Infections.
What interventions are being tested in trial NCT01844856?
The interventions under investigation include: Placebo (DRUG), Eravacycline (DRUG), Ertapenem (DRUG).
Who is sponsoring clinical trial NCT01844856?
This trial is sponsored by Tetraphase Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01844856 being conducted?
This trial has 20 study locations across Alabama, California, Illinois, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.